keyword
MENU ▼
Read by QxMD icon Read
search

Statin and cognition

keyword
https://www.readbyqxmd.com/read/28637375/anticoagulant-therapy-for-recurrent-in-stent-thrombosis-following-carotid-artery-stenting-a-case-report
#1
Akinori Miyakoshi, Hiroki Toda, Makoto Hayase, Takeshi Kawauchi, Yuki Oichi, Etsuko Hattori
We report a case in which strict anticoagulant therapy management was useful for a recurrent in-stent thrombosis after carotid artery stenting (CAS). An 84-year-old man presented with cognitive decline that progressed rapidly over two months. Head magnetic resonance imaging showed an acute-stage infarct occurring frequently in the right cerebral hemisphere, and he underwent hospitalization and treatment. On neck magnetic resonance angiography (MRA), severe stenosis was found at the origin of the right internal carotid artery...
January 1, 2017: Interventional Neuroradiology
https://www.readbyqxmd.com/read/28611866/association-of-cognitive-impairment-in-patients-on-3-hydroxy-3-methyl-glutaryl-coa-reductase-inhibitors
#2
Satyajeet Roy, Joshua Louis Weinstock, Allyse Sachiko Ishino, Jefferson Felix Benites, Samantha Rachel Pop, Christopher David Perez, Edvard Adrian Gumbs, Jennifer Ann Rosenbaum, Mary Kate Roccato, Hely Shah, Gabriela Contino, Krystal Hunter
BACKGROUND: Atherosclerotic cardiovascular diseases are the leading cause of death in the United States. A reduction in cholesterol with 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statin) significantly reduces mortality and morbidity. Statins may be associated with cognitive impairment or dementia. Our aim was to study the association of cognitive impairment or dementia in patients who were on a statin. METHODS: Electronic medical records of 3,500 adult patients in our suburban internal medicine office were reviewed...
July 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28583470/insights-into-the-current-management-of-older-adults-with-type-2-diabetes-in-the-ontario-primary-care-setting
#3
Graydon S Meneilly, Lori D Berard, Alice Y Y Cheng, Peter J Lin, Lori MacCallum, Ross T Tsuyuki, Jean-François Yale, Nahal Nasseri, Jean-François Richard, Lianne Goldin, Anatoly Langer, Mary K Tan, Lawrence A Leiter
OBJECTIVE: The Goal Oriented controL of Diabetes in the Elderly populatioN (GOLDEN) Program assessed the management of older persons with type 2 diabetes in Canadian primary care. METHODS: Data were extracted from the records of 833 consecutively identified persons 65 years of age or older who had type 2 diabetes and were taking 1 antihyperglycemic agent or more; they were managed by 64 physicians from 36 Ontario clinics. RESULTS: More than half (53%) had glycated hemoglobin (A1C) levels of 7...
June 2, 2017: Canadian Journal of Diabetes
https://www.readbyqxmd.com/read/28520522/perceptions-of-statin-discontinuation-among-patients-with-life-limiting-illness
#4
Jennifer Tjia, Jean S Kutner, Christine S Ritchie, Patrick J Blatchford, Rachael E Bennett Kendrick, Maryjo Prince-Paul, Tamara J Somers, Mary Lynn McPherson, Jeff A Sloan, Amy P Abernethy, Jon P Furuno
BACKGROUND: Optimal management of chronic medications for patients with life-limiting illness is uncertain. Medication deprescribing may improve outcomes in this population, but patient concerns regarding deprescribing are unclear. OBJECTIVE: The aim of this study was to quantify the perceived benefits and concerns of statin discontinuation among patients with life-limiting illness. DESIGN: Baseline data from a multicenter, pragmatic clinical trial of statin discontinuation were used...
May 18, 2017: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/28499972/simvastatin-ameliorates-memory-impairment-and-neurotoxicity-in-streptozotocin-induced-diabetic-mice
#5
Shun-Chang Fang, Hang Xie, Fang Chen, Mei Hu, Yan Long, Hong-Bin Sun, Ling-Yi Kong, Hao Hong, Su-Su Tang
Diabetes comes with an additional burden of moderate to severe hyperlipidemia, but little is known about the effects of lipid-lowering therapy on diabetic complications such as diabetes-associated cognitive decline. Herein we investigated the effects of statins on memory impairment and neurotoxicity in streptozotocin-induced diabetic mice. Our data indicated that oral administration of simvastatin at 10 or 20mg/kg for 4weeks significantly ameliorated diabetes-associated memory impairment reflected by performance better in the Morris water maze and Y-maze tests...
May 10, 2017: Neuroscience
https://www.readbyqxmd.com/read/28480324/the-effect-of-statins-on-rate-of-cognitive-decline-in-mild-cognitive-impairment
#6
Kyle B Smith, Paul Kang, Marwan N Sabbagh
OBJECTIVE: This study's aims are to identify whether or not a relationship between statin use and rate of cognitive decline exists. BACKGROUND: The relationship between statins and MCI has been investigated in the past with the evidence showing mixed results. METHODS: 768 subjects were identified with MCI. Subjects were stratified into 6 possible groups according to ApoE4 status and statin use and assessed for decline in cognitive function...
June 2017: Alzheimer's & Dementia: Translational Research & Clinical Interventions
https://www.readbyqxmd.com/read/28476288/adverse-events-associated-with-unblinded-but-not-with-blinded-statin-therapy-in-the-anglo-scandinavian-cardiac-outcomes-trial-lipid-lowering-arm-ascot-lla-a-randomised-double-blind-placebo-controlled-trial-and-its-non-randomised-non-blind-extension-phase
#7
Ajay Gupta, David Thompson, Andrew Whitehouse, Tim Collier, Bjorn Dahlof, Neil Poulter, Rory Collins, Peter Sever
BACKGROUND: In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational studies, larger increases in many different AEs have been reported than in blinded trials. METHODS: In the Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial, patients aged 40-79 years with hypertension, at least three other cardiovascular risk factors, and fasting total cholesterol concentrations of 6·5 mmol/L or lower, and who were not taking a statin or fibrate, had no history of myocardial infarction, and were not being treated for angina were randomly assigned to atorvastatin 10 mg daily or matching placebo in a randomised double-blind placebo-controlled phase...
May 2, 2017: Lancet
https://www.readbyqxmd.com/read/28453187/pcsk9-monoclonal-antibodies-for-the-primary-and-secondary-prevention-of-cardiovascular-disease
#8
REVIEW
Amand F Schmidt, Lucy S Pearce, John T Wilkins, John P Overington, Aroon D Hingorani, Juan P Casas
BACKGROUND: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL-C reduction may be warranted, especially for patients who are unresponsive to, or unable to take, existing LDL-C-reducing therapies. By inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme, monoclonal antibodies (PCSK9 inhibitors) may further reduce LDL-C, potentially reducing CVD risk as well...
April 28, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28401726/the-genomic-potential-of-the-aspirin-in-reducing-events-in-the-elderly-and-statins-in-reducing-events-in-the-elderly-studies
#9
Paul Lacaze, Robyn Woods, Sophia Zoungas, John McNeil
Human genetic studies are continuing to increase in size and scale, but the availability of well-phenotyped longitudinal cohorts remains rare. Significant infrastructure, investment and effort are required to establish and maintain high-quality cohorts with biobanking, genetic consent and repeated clinical data measurements. Australia currently has two such cohorts established by Monash University as part of community-based clinical trials in the elderly. Both studies involve capture of demographic, mood, cognitive performance, physical function, neuroimaging, audiometry and various clinical data types over an average of 5 years...
April 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28363508/risk-factors-associated-with-the-onset-and-progression-of-alzheimer-s-disease-a-systematic-review-of-the-evidence
#10
Mona Hersi, Brittany Irvine, Pallavi Gupta, James Gomes, Nicholas Birkett, Daniel Krewski
A systematic review was conducted to identify risk factors associated with the onset and progression of Alzheimer's disease (AD). Moderate and high quality systematic reviews were eligible for inclusion. Primary studies reporting on non-genetic risk factors associated with neuropathologically or clinically confirmed AD were considered. Eighty one systematic reviews reporting on AD onset and 12 reporting on progression satisfied the eligibility criteria. Four hundred and thirty-two relevant primary studies reporting on onset were identified; however, only those published between 2010 and 2012 (n=65) were included in the qualitative synthesis...
March 28, 2017: Neurotoxicology
https://www.readbyqxmd.com/read/28321063/a-pilot-study-the-beneficial-effects-of-combined-statin-exercise-therapy-on-cognitive-function-in-patients-with-coronary-artery-disease-and-mild-cognitive-decline
#11
Kensuke Toyama, Seigo Sugiyama, Hideki Oka, Mari Hamada, Yuri Iwasaki, Eiji Horio, Taku Rokutanda, Shinichi Nakamura, Joshua M Spin, Philip S Tsao, Hisao Ogawa
Objective Hypercholesterolemia, a risk factor in cognitive impairment, can be treated with statins. However, cognitive decline associated with "statins" (HMG-CoA reductase inhibitors) is a clinical concern. This pilot study investigated the effects of combining statins and regular exercise on cognitive function in coronary artery disease (CAD) patients with prior mild cognitive decline. Methods We recruited 43 consecutive CAD patients with mild cognitive decline. These patients were treated with a statin and weekly in-hospital aerobic exercise for 5 months...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28295777/can-ldl-cholesterol-be-too-low-possible-risks-of-extremely-low-levels
#12
A G Olsson, B Angelin, G Assmann, C J Binder, I Björkhem, A Cedazo-Minguez, J Cohen, A von Eckardstein, E Farinaro, D Müller-Wieland, K G Parhofer, P Parini, R S Rosenson, J Starup-Linde, M J Tikkanen, L Yvan-Charvet
Following the continuous accumulation of evidence supporting the beneficial role of reducing low-density lipoprotein cholesterol (LDL-C) levels in the treatment and prevention of atherosclerotic cardiovascular disease and its complications, therapeutic possibilities now exist to lower LDL-C to very low levels, similar to or even lower than those seen in newborns and nonhuman species. In addition to the important task of evaluating potential side effects of such treatments, the question arises whether extremely low LDL-C levels per se may provoke adverse effects in humans...
June 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28279605/memory-alterations-and-white-matter-hyperintensities-in-elderly-patients-with-hypertension-the-adelahyde-2-study
#13
João Pedro Ferreira, Anna Kearney Schwartz, Ghassan Watfa, Lamiral Zohra, Jacques Felblinger, Jean-Marc Boivin, Serge Bracard, Gabriella Hossu, Antoine Verger, Laure Joly, Faiez Zannad, Patrick Rossignol, Athanase Benetos
OBJECTIVES: The longitudinal ADELAHYDE-2 study aims to identify the factors associated with cognitive impairment/decline and white matter hyperintensities burden. METHODS: Longitudinal single-center study comprising two visits separated by approximately 7 years. A total of 131 patients completed the two visits. The primary outcome was global memory composite scale, while the secondary outcome was white matter hyperintensities (WMH/Fazekas scale) load. RESULTS: Global memory at visit 2 (V2) was largely influenced by age, smoking status, glycated hemoglobin, and history of stroke already present at visit 1 (V1)...
May 1, 2017: Journal of the American Medical Directors Association
https://www.readbyqxmd.com/read/28274859/longitudinal-lipid-profile-variations-and-clinical-change-in-alzheimer-s-disease-dementia
#14
Fabricio Ferreira de Oliveira, Elizabeth Suchi Chen, Marilia Cardoso Smith, Paulo Henrique Ferreira Bertolucci
Hypercholesterolemia and statin use have been unevenly associated with clinical change in Alzheimer's disease dementia. In this longitudinal study, 192 consecutive outpatients with late-onset Alzheimer's disease dementia were stratified according to APOE haplotypes, and followed for one year to investigate associations of lipid profile variations and lipophilic statin therapy with changes in cognition, caregiver burden, basic and instrumental functionality. Overall, 102 patients (53.1%) carried APOE4+ haplotypes and 90 (46...
April 12, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28261092/screening-for-small-molecule-inhibitors-of-statin-induced-app-c-terminal-toxic-fragment-production
#15
Karen S Poksay, Douglas J Sheffler, Patricia Spilman, Jesus Campagna, Barbara Jagodzinska, Olivier Descamps, Olivia Gorostiza, Alex Matalis, Michael Mullenix, Dale E Bredesen, Nicholas D P Cosford, Varghese John
Alzheimer's disease (AD) is characterized by neuronal and synaptic loss. One process that could contribute to this loss is the intracellular caspase cleavage of the amyloid precursor protein (APP) resulting in release of the toxic C-terminal 31-amino acid peptide APP-C31 along with the production of APPΔC31, full-length APP minus the C-terminal 31 amino acids. We previously found that a mutation in APP that prevents this caspase cleavage ameliorated synaptic loss and cognitive impairment in a murine AD model...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28228632/physical-and-psychological-characteristics-of-the-community-dwelling-elderly-with-heart-disease
#16
Takeshi Kera, Hisashi Kawai, Hideyo Yoshida, Hirohiko Hirano, Motonaga Kojima, Yoshinori Fujiwara, Kazushige Ihara, Shuichi Obuchi
Objectives Although the survival rates of patients with heart diseases, such as myocardial infarction and heart failure, have increased, the incidence of heart disease in elderly individuals has also increased. We compared characteristics of the community-dwelling elderly with heart diseases (heart disease group) and without heart diseases (non-heart disease group).Methods A total of 758 elderly individuals participated in our survey ("Otassha-kensin") in 2014. The heart disease group (47 men, 28 women) and the non-heart disease group (263 men, 420 women) were selected from among these participants...
2017: [Nihon Kōshū Eisei Zasshi] Japanese Journal of Public Health
https://www.readbyqxmd.com/read/28217821/physicians-experiences-as-patients-with-statin-side-effects-a-case-series
#17
Hayley J Koslik, Athena Hathaway Meskimen, Beatrice Alexandra Golomb
Physicians are among those prescribed statins and therefore, subject to potential statin adverse effects (AEs). There is little information on the impact of statin AEs on physicians affected by them. We sought to assess the character and impact of statin AEs occurring in physicians and retired physicians, and to ascertain whether/how personal experience of AEs moderated physicians' attitude toward statin use. Seven active or retired physicians from the United States communicated with the Statin Effects Study group regarding their personal experience of statin AEs...
December 2017: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/28212683/evidence-for-benefit-of-statins-to-modify-cognitive-decline-and-risk-in-alzheimer-s-disease
#18
Nophar Geifman, Roberta Diaz Brinton, Richard E Kennedy, Lon S Schneider, Atul J Butte
BACKGROUND: Despite substantial research and development investment in Alzheimer's disease (AD), effective therapeutics remain elusive. Significant emerging evidence has linked cholesterol, β-amyloid and AD, and several studies have shown a reduced risk for AD and dementia in populations treated with statins. However, while some clinical trials evaluating statins in general AD populations have been conducted, these resulted in no significant therapeutic benefit. By focusing on subgroups of the AD population, it may be possible to detect endotypes responsive to statin therapy...
February 17, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/28207168/design-and-rationale-of-the-ebbinghaus-trial-a-phase-3-double-blind-placebo-controlled-multicenter-study-to-assess-the-effect-of-evolocumab-on-cognitive-function-in-patients-with-clinically-evident-cardiovascular-disease-and-receiving-statin-background-lipid
#19
RANDOMIZED CONTROLLED TRIAL
Robert P Giugliano, Francois Mach, Kenton Zavitz, Christopher Kurtz, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R Pedersen, Marc S Sabatine, Peter S Sever, Narimon Honarpour, Scott M Wasserman, Brian R Ott
Some observational studies raised concern that statins may cause memory impairment, leading to a US Food and Drug Administration warning. Similar questions were raised regarding proprotein convertase subtilisin/kexin-type 9 inhibitors (PCSK9i) and neurocognitive function. No prospectively designed study has evaluated the relationship between long-term PCSK9i use and cognition changes. Patients with prior cardiovascular disease treated with maximally tolerated statin enrolled in FOURIER (the randomized, double-blind, placebo-controlled cardiovascular outcome study of the PCSK9i evolocumab) could participate in this prospective assessment of cognitive function (EBBINGHAUS)...
February 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/28195516/young-adulthood-cognitive-ability-predicts-statin-adherence-in-middle-aged-men-after-first-myocardial-infarction-a-swedish-national-registry-study
#20
John Wallert, Claudia Lissåker, Guy Madison, Claes Held, Erik Olsson
Background Cognitive ability (CA) is positively related to later health, health literacy, health behaviours and longevity. Accordingly, a lower CA is expected to be associated with poorer adherence to medication. We investigated the long-term role of CA in adherence to prescribed statins in male patients after a first myocardial infarction (MI). Methods CA was estimated at 18-20 years of age from Military Conscript Register data for first MI male patients (≤60 years) and was related to the one- and two-year post-MI statin adherence on average 30 years later...
April 2017: European Journal of Preventive Cardiology
keyword
keyword
89667
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"